Flamel Technologies SA (NASDAQ: FLML) is a leading drug delivery company focused on the goal of developing safer, more efficacious formulations of drugs to tackle unmet medical needs.
Our product development pipeline includes biological and chemical drugs formulated with our proprietary platforms, Medusa® and Micropump®.
Strategy
In March 2012, Flamel has acquired Éclat Pharmaceuticals, a specialty pharmaceutical company focused on the development, approval, and commercialization of niche brands and generic products. This acquisition creates a more vertically integrated company, benefiting from greater development and commercial expertise, best in class drug delivery platforms and more near-term and mid-term potential value creating catalysts.
Partnerships
Flamel Technologies has collaborations with a number of leading pharmaceutical and biotechnology companies, including GlaxoSmithKline and Merck Serono .
Success
Flamel Technologies has drugs approved in the USA and in some European countries (Coreg CR® and Micropump Aspirin, respectively) and manufactures Micropump-based products.
Medusa platform (injectable drugs) allows formulation and/or extended release of biologics (including proteins, antibodies and peptides) and also small molecules.
Several Medusa-based products are at various clinical stages of development; Medusa’s lead internal product candidate IFN-α XL is currently the subject of a Phase 2 trial in HCV patients.
DeliVax®, Medusa’s vaccine application, permits the efficient formulation of vaccines.
Micropump platform (oral drugs) allows formulation and controlled release of chemical drugs that are best absorbed in the small intestine.
LiquiTime® allows extended release liquid formulations of drugs for patients who have difficulty swallowing tablets or capsules, particularly children and the elderly.
Trigger Lock™ allows tamper-resistant controlled release formulations of narcotics and other drugs susceptible to abuse.
